Original Research
Original Research
Brain Atrophy, Cognitive Decline, and First-Episode Psychosis
November 11, 2021
The etiology of first-episode psychosis (FEP) in the elderly is unknown, but an underlying neurodegenerative disorder may be an important factor. To investigate further, this study assessed brain atrophy...
Original Research
COVID-19 and Consultation-Liaison Psychiatry Services
October 21, 2021
COVID-19 has affected all aspects of psychiatric care, including consultation-liaison psychiatry services. This study assessed demographic and clinical profiles of psychiatric referrals during the pandemic compared to the previous...
Original Research
Continuation MST for Treatment-Resistant Depression
October 19, 2021
Magnetic seizure therapy (MST) has shown promise as an alternative to electroconvulsive therapy for acute treatment-resistant depression (TRD). This study examines the efficacy of MST as a continuation treatment...
Original Research
Combat Exposure and Suicide Risk in Military Personnel
October 12, 2021
Information on the relationship between combat exposure level and post-deployment suicide attempt risk is sparse. This study estimated the association between self-reported perceived danger during military deployment and post-deployment...
Original Research
Efficacy of Peers in Addiction Training for Internal Medicine Residents
October 7, 2021
Internists often care for patients with substance use disorders but do not receive adequate training. This study sought to improve internal medicine residents’ attitudes regarding substance use disorders with...
Original Research
Aripiprazole Once Monthly in Recent-Onset Schizophrenia
September 30, 2021
This study compared time to discontinuation and clinical outcomes of aripiprazole once-monthly 400 mg versus oral atypical antipsychotics in patients with recent-onset schizophrenia in a naturalistic setting. Read on...
Original Research
Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis
September 21, 2021
Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
